SI2134702T2 - Kristalinične oblike 6-(2-(metilkarbamoil)fenilsulfanil)-3-E-(2-(piridin-2-il)etenil)indazola primerne za zdravljenje abnormalne rasti celic pri sesalcih - Google Patents

Kristalinične oblike 6-(2-(metilkarbamoil)fenilsulfanil)-3-E-(2-(piridin-2-il)etenil)indazola primerne za zdravljenje abnormalne rasti celic pri sesalcih

Info

Publication number
SI2134702T2
SI2134702T2 SI200831821T SI200831821T SI2134702T2 SI 2134702 T2 SI2134702 T2 SI 2134702T2 SI 200831821 T SI200831821 T SI 200831821T SI 200831821 T SI200831821 T SI 200831821T SI 2134702 T2 SI2134702 T2 SI 2134702T2
Authority
SI
Slovenia
Prior art keywords
phenylsulfanyl
methylcarbamoyl
indazole
ethenyl
pyridin
Prior art date
Application number
SI200831821T
Other languages
English (en)
Other versions
SI2134702T1 (sl
Inventor
Anthony Michael Campeta
Brian Patrick Chekal
Robert William Mclaughling
Robert Alan Singer
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2134702(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of SI2134702T1 publication Critical patent/SI2134702T1/sl
Publication of SI2134702T2 publication Critical patent/SI2134702T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
SI200831821T 2007-04-05 2008-03-25 Kristalinične oblike 6-(2-(metilkarbamoil)fenilsulfanil)-3-E-(2-(piridin-2-il)etenil)indazola primerne za zdravljenje abnormalne rasti celic pri sesalcih SI2134702T2 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91037907P 2007-04-05 2007-04-05
US97654607P 2007-10-01 2007-10-01
US3155408P 2008-02-26 2008-02-26
EP08719405.6A EP2134702B2 (en) 2007-04-05 2008-03-25 Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
PCT/IB2008/000792 WO2008122858A2 (en) 2007-04-05 2008-03-25 Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals

Publications (2)

Publication Number Publication Date
SI2134702T1 SI2134702T1 (sl) 2017-07-31
SI2134702T2 true SI2134702T2 (sl) 2023-12-29

Family

ID=39831473

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831821T SI2134702T2 (sl) 2007-04-05 2008-03-25 Kristalinične oblike 6-(2-(metilkarbamoil)fenilsulfanil)-3-E-(2-(piridin-2-il)etenil)indazola primerne za zdravljenje abnormalne rasti celic pri sesalcih

Country Status (23)

Country Link
US (1) US8791140B2 (sl)
EP (4) EP4074702A1 (sl)
JP (2) JP5869197B2 (sl)
KR (1) KR101237588B1 (sl)
CN (2) CN101679356A (sl)
AR (1) AR065931A1 (sl)
AU (1) AU2008236444B2 (sl)
BR (1) BRPI0809471A2 (sl)
CA (1) CA2682859C (sl)
CY (1) CY1119119T1 (sl)
DK (1) DK2134702T4 (sl)
ES (2) ES2634866T5 (sl)
FI (1) FI2134702T4 (sl)
HK (1) HK1193405A1 (sl)
IL (1) IL201320A (sl)
MX (1) MX2009010761A (sl)
NZ (1) NZ580126A (sl)
PL (1) PL2134702T5 (sl)
PT (1) PT2134702T (sl)
RU (1) RU2518898C2 (sl)
SI (1) SI2134702T2 (sl)
TW (1) TWI481602B (sl)
WO (1) WO2008122858A2 (sl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4074702A1 (en) 2007-04-05 2022-10-19 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
KR20140069297A (ko) * 2011-09-30 2014-06-09 화이자 인코포레이티드 N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물
RU2014116407A (ru) 2011-11-11 2015-12-20 Пфайзер Инк. N-метил-2-[3-((e)-2-пиридин-2-ил-винил)-1н-индазол-6-илсульфанил]-бензамид для лечения хронического миелоидного лейкоза
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN104230886A (zh) * 2013-06-24 2014-12-24 南京华威医药科技开发有限公司 阿昔替尼新晶型
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
CN104650034A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 一种稳定的阿西替尼化合物
AU2015214390B2 (en) 2014-02-04 2020-05-07 Merck Sharp & Dohme LLC. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
EP3127900B1 (en) * 2014-03-31 2017-10-18 Senju Pharmaceutical Co., Ltd. Alkynyl indazole derivative and use thereof
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
EP4279087A3 (en) 2015-02-26 2024-01-31 Merck Patent GmbH Pd-1 / pd-l1 inhibitors for the treatment of cancer
WO2016178150A1 (en) * 2015-05-05 2016-11-10 Shilpa Medicare Limited Novel polymorphs of axitinib
MX2017016324A (es) 2015-06-16 2018-03-02 Merck Patent Gmbh Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
TW201808910A (zh) 2016-05-16 2018-03-16 帝人製藥股份有限公司 喹啉衍生物之結晶
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
CN106883212A (zh) * 2017-03-16 2017-06-23 合肥拓锐生物科技有限公司 一种xli晶型阿昔替尼的制备方法
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EP3965743A1 (en) 2019-05-09 2022-03-16 Synthon B.V. Pharmaceutical composition comprising axitinib
CN111187253B (zh) * 2020-01-09 2023-05-09 鲁南制药集团股份有限公司 一种阿昔替尼新晶型
HRP20230800T1 (hr) 2020-03-25 2023-10-27 Ocular Therapeutix, Inc. Očni usadak koji sadrži inhibitor tirozin kinaze
WO2022000265A1 (zh) * 2020-06-30 2022-01-06 天津理工大学 一种阿西替尼与戊二酸共晶及其制备方法
CN113943271B (zh) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN113943270B (zh) * 2020-07-15 2023-05-09 鲁南制药集团股份有限公司 一种阿昔替尼晶型
CN114685436B (zh) * 2020-12-25 2022-12-02 鲁南制药集团股份有限公司 阿昔替尼糖精共晶水合物
CN114685437B (zh) * 2020-12-25 2022-12-09 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685431B (zh) * 2020-12-26 2022-11-29 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685432B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法
CN114685434B (zh) * 2020-12-28 2023-06-16 鲁南制药集团股份有限公司 一种阿昔替尼与戊二酸共晶
CN114685433B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备
CN114685435B (zh) * 2020-12-28 2023-01-31 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
WO2023166418A2 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
KR20020071931A (ko) † 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2004226586B2 (en) 2003-04-03 2008-12-11 Pfizer Inc. Dosage forms comprising AG013736
AU2005300310A1 (en) * 2004-11-02 2006-05-11 Pfizer Inc. Methods of preparing indazole compounds
WO2006048745A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Methods for preparing indazole compounds
CN101052633A (zh) 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
WO2006048746A2 (en) 2004-11-02 2006-05-11 Pfizer Inc. Methods for the removal of heavy metals
AU2005300317A1 (en) * 2004-11-02 2006-05-11 Pfizer Inc. Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole
WO2006123223A1 (en) 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP4074702A1 (en) 2007-04-05 2022-10-19 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
KR20140069297A (ko) † 2011-09-30 2014-06-09 화이자 인코포레이티드 N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물

Also Published As

Publication number Publication date
KR101237588B1 (ko) 2013-02-27
DK2134702T4 (da) 2023-09-25
WO2008122858A9 (en) 2009-06-18
HK1193405A1 (zh) 2014-09-19
TWI481602B (zh) 2015-04-21
KR20090127949A (ko) 2009-12-14
ES2634866T3 (es) 2017-09-29
RU2009136593A (ru) 2011-04-10
EP4249063A3 (en) 2024-03-13
DK2134702T3 (en) 2017-08-21
IL201320A (en) 2016-05-31
JP5869197B2 (ja) 2016-02-24
PT2134702T (pt) 2017-07-31
EP2134702B1 (en) 2017-05-31
CN101679356A (zh) 2010-03-24
EP3252047B1 (en) 2022-05-11
EP3252047A2 (en) 2017-12-06
FI2134702T4 (fi) 2023-09-12
ES2919351T3 (es) 2022-07-26
TW200911781A (en) 2009-03-16
CA2682859C (en) 2013-10-08
AU2008236444A1 (en) 2008-10-16
CN103626739A (zh) 2014-03-12
NZ580126A (en) 2012-03-30
EP2134702B2 (en) 2023-08-30
PL2134702T3 (pl) 2017-10-31
EP4074702A1 (en) 2022-10-19
US8791140B2 (en) 2014-07-29
US20100179329A1 (en) 2010-07-15
CY1119119T1 (el) 2018-02-14
ES2634866T5 (es) 2024-03-04
AU2008236444B2 (en) 2012-06-28
SI2134702T1 (sl) 2017-07-31
CA2682859A1 (en) 2008-10-16
WO2008122858A2 (en) 2008-10-16
EP2134702A2 (en) 2009-12-23
AR065931A1 (es) 2009-07-08
WO2008122858A3 (en) 2009-05-07
EP4249063A2 (en) 2023-09-27
EP3252047A3 (en) 2018-08-15
PL2134702T5 (pl) 2023-12-04
WO2008122858A8 (en) 2009-11-26
MX2009010761A (es) 2009-10-28
IL201320A0 (en) 2010-05-31
RU2518898C2 (ru) 2014-06-10
JP2014193900A (ja) 2014-10-09
JP2009019030A (ja) 2009-01-29
CN103626739B (zh) 2015-12-30
BRPI0809471A2 (pt) 2014-09-09

Similar Documents

Publication Publication Date Title
SI2134702T2 (sl) Kristalinične oblike 6-(2-(metilkarbamoil)fenilsulfanil)-3-E-(2-(piridin-2-il)etenil)indazola primerne za zdravljenje abnormalne rasti celic pri sesalcih
TWI369205B (en) Sulfonyl amide derivatives for the treatment of abnormal cell growth
ZA200804488B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
PL2409727T3 (pl) Urządzenia elektroporacyjne do elektroporacji komórek u ssaków
IL211176A0 (en) Methods for the production of ips cells
HK1126121A1 (en) Method of treating abnormal cell growth
PL2321295T3 (pl) Pochodne 4-(pirydyn-4-ylo)-1H-[1,3,5]triazyn -2-onu jako inhibitory GSK2-beta do leczenia chorób degeneracyjnych
ZA201005208B (en) Process for the manufacture of solar cells
IL178828A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
GB2467710B (en) Methods for treating social disorders
IL216084A0 (en) 2,4-diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
EP2154242A4 (en) METHOD FOR INDUCING MYOCARDIAL CELL DIFFERENTIATION USING G-CSF
WO2010083240A9 (en) Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds
GB0814443D0 (en) Process for cultivating cells
ZA200906990B (en) Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
EP2172562A4 (en) PROCESS FOR INTEGRATING NON-INVASIVE BACTERIA IN EUKARYOTIC CELLS
HUP0700350A2 (en) Process for increasing the number of stem cells in the blood circulation
PL389673A1 (pl) Nowe pochodne 1-(2-pirydylo)-6-podstawione imidazo [1, 2-a][1, 3, 5] triazyny oraz sposób ich wytwarzania
AU2008900382A0 (en) Method for treating B cell disorders
IL192452A (en) A process for producing titanium salts
GB0812609D0 (en) Process for the preparation of deoxynojirimycin